FRM
RVMD icon

Fox Run Management’s Revolution Medicines RVMD Stock Holding History

Fox Run Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,391
Closed -$509K – 1192
2025
Q4 		$509K Buy
+6,391
New +$419K 0.08% 494
2025
Q3 		– Sell
-18,303
Closed -$673K – 1198
2025
Q2 		$673K Buy
+18,303
New +$703K 0.11% 338
2024
Q1 		– Sell
-7,961
Closed -$228K – 1021
2023
Q4 		$228K Buy
+7,961
New +$191K 0.06% 598

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fox Run Management's RVMD Position: Q1 2026 in Review

Fox Run Management sold out of Revolution Medicines (RVMD) in Q1 2026, closing a stake of 6,391 shares — an estimated $509K sold.

Fox Run Management first reported a position in RVMD in Q4 2023 and held it in 3 quarters. The position peaked at $673K in Q2 2025. 514 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Fox Run Management reported no remaining Revolution Medicines position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 6,391 Revolution Medicines shares in Q1 2026, an estimated $509K.
  • Fox Run Management first reported a position in Revolution Medicines in Q4 2023 and held it in 3 quarters.
  • Fox Run Management's Revolution Medicines position peaked at $673K in Q2 2025.
  • 514 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.